Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective

已完结 10 由 crethy 发布于 2026/11/13 15:06:53

DOI:10.1016/j.retram.2026.103576
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/j.retram.2026.103576

Elsevier

Abstract：PurposeThe combination of cladribine (CLAD), low-dose cytarabine (LDAC), and venetoclax (CLAD-LDAC-venetoclax) has demonstrated promising efficacy in acute myeloid leukemia (AML) but remains

应助信息

46分钟前

iwu

b491bdf9df3111f195f6208810ba6e4f.pdf 已采纳

53分钟前

Book学术机器人

2026/11/13 15:06:53 未找到该文献，机器人已退出，请等待人工下载

2026/11/13 15:06:53 Book学术AI机器人收到请求，开始寻找文献

2026/11/13 15:06:53 已向机器人发送请求

53分钟前

crethy 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库FIF: future interaction forecasted for multi-agent trajectory prediction